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Abstract
Background: Fabry disease (FD, OMIM 301500) is an X-linked inborn error of glycosphingolipid
metabolism due to the deficient activity of alpha-galactosidase A, a lysosomal enzyme. While the
progressive systemic deposition of uncleaved glycosphingolipids throughout the body is known to
have protean clinical manifestations, few data are available regarding the cochlear involvement.
Methods: We non-invasively investigated cochlear functions in 22 consecutive hemizygous males
(age 19–64 years, mean 39) affected with classic FD. Conventional audiometry, tympanometry,
ABR audiometry, otoacoustic emissions were performed in all patients, together with medical
history record and physical examination as part of an exhaustive baseline evaluation prior to
enzyme replacement therapy.
Results: A total of 12 patients (54.5%) with classic FD were found to have abnormal audition. Five
patients had progressive hearing loss and seven patients (32%) experienced sudden deafness. In
addition, a hearing loss on high-tone frequencies was found in 7 out of the 10 remaining patients
without clinical impairment, despite their young age at time of examination. The incidence of
hearing loss appeared significantly increased in FD patients with kidney failure (P < 0.01) or
cerebrovascular lesions (P < 0.01), whereas there was no correlation with left ventricular
hypertrophy. In addition, tinnitus aurium was also found in six patients (27%).
Conclusion: This is the first evidence of a high incidence of both progressive hearing loss and
sudden deafness in a cohort of male patients affected with classic Fabry disease. The exact
pathophysiologic mechanism(s) of the cochlear involvement deserves further studies.
Background
Fabry disease (FD, OMIM 301500) is an X-linked inherit-
ed disorder of sphingolipids metabolism due to the defi-
cient activity of -galactosidase A (EC EC 3.2.1.22), a
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lysosomal enzyme [1]. The enzyme deficiency leads to the
widespread deposition of neutral glycosphingolipids
(mainly globotriaosylceramide, and, to a lesser extent,
galabiosylceramide) [2] in plasma and lysosomes
throughout the body. Initial symptoms of FD include an-
giokeratoma, acroparesthesia, autonomic dysfunction,
and corneal opacities. Progressive glycolipid deposition in
the endothelial and smooth muscle cells of the microvas-
culature of affected patients leads to the narrowing and
thrombosis of small arteries and arterioles, then to ischae-
mic complications involving brain, and heart, together
with chronic renal insufficiency and early death [3–5].
Although FD is a paradigm for multi-systemic inherited
disorder of metabolism, little is known about the patho-
genesis of cochlear lesions and there has been a limited lit-
erature about cochleovestibular involvement in FD. One
paper reported the histology of temporal bones in two pa-
tients [6], whose audiograms exhibited a bilateral sen-
sorineural hearing loss audiometrically. Middle ear
findings of seropurulent effusions and hyperplastic muco-
sa were seen in temporal bones of both patients. Strial and
spiral ligament atrophy in all turns, and hair cell loss
mainly in the basal turns, were also common findings.
The number of spiral ganglion cells was reduced in all
temporal bones. However, evidence of glycosphingolipid
accumulation was not observed in the spiral ganglia [6].
Much interest is currently paid to emerging therapies, and
recent studies have demonstrated that genetic engineering
has removed many of the obstacles to the clinical use of
enzyme replacement, and that infusions of purified -ga-
lactosidase A are safe and biochemically active [7,8].
However, the slow course of the disease emphasizes the
need for development of clinical or surrogate endpoints,
using non-invasive validated methodologies to delineate
target organ damage and monitor the efficacy of emerging
therapy with -galactosidase A on various endpoints.
In the present study, we hypothesized that the auditory
functions could be altered in response to glycosphingoli-
pid deposition. With this respect, we carried out a com-
plete baseline auditory examination in a large cohort of
22 hemizygotes affected with Fabry disease, prior to en-
zyme replacement therapy.
Methods
Subjects
We examined 22 consecutive hemizygous male patients
(19–64 years old, mean 39, SD 13.6) affected with classic
FD from 17 unrelated pedigrees followed at the Clinical
Genetics Unit of the Georges Pompidou European Hospi-
tal. All diagnose were made by one of us (DPG) from clin-
ical features, and confirmed by demonstration of a 4-
methyl umbelliferyl--galactosidase activity <2.5 nmol/h/
mg of proteins in peripheral blood leukocytes (normal
values: 25–55 nmol/h/mg of proteins). No results of ex-
aminations on any of our patients have been published
previously.
The patients were referred to the Auditory Research Labo-
ratory (PA, PB) for complete auditory examination as part
of an extensive baseline evaluation before enzyme re-
placement therapy. Subjects with a history of trauma, oto-
logic surgery, ototoxic reactions including
aminoglycoside exposure, noise exposure, or concurrent
medical conditions known to cause hearing loss were ex-
cluded from this analysis. There was no history of inherit-
ed deafness, unlinked to Fabry disease, in any of the 17
pedigrees. All subjects gave informed consent prior to par-
ticipation.
Audiologic evaluation
All patients were studied in a quiet room with controlled
temperature of 22  1C by a unique senior investigator,
trained and certified in ENT medicine (PB). Otolaryngo-
logical histories were obtained, and physical examina-
tions, including pneumatic otoscopy, were performed on
each subject. Audiologic evaluations consisted of pure-
tone air and bone conduction audiometry, speech audi-
ometry, and middle-ear immitance testing (tympanome-
try and acoustic reflex testing). All patients also
underwent transient-evoked, distortion otoacoustic emis-
sions testing, using an ILO96 Otodynamic analyzer previ-
ously validated in clinical studies (Otodynamics, London,
England), and auditory brainstem response (ABR) audi-
ometry using an Auris apparatus (Synapsys, Marseille,
France).
Clinical data analysis
The type of hearing loss (HL) was classified as sen-
sorineural, conductive, or mixed according to the Europe-
an Working Group on Genetics of Hearing Impairment
[http://www.gendeaf.org]. Conductive hearing loss was
defined as normal bone conduction thresholds (<20 dB
HL), and an average air-bone gap of 15 dB or more for 0.5,
1, and 2 kHz. Mixed hearing loss was defined as a bone
conduction threshold greater than 20 dB HL in combina-
tion with an averaged air-bone gap 15 dB or more for 0.5,
1 and 2 kHz. Sensorineural hearing loss was defined as an
averaged air-bone gap of less than 15 dB for 0.5, 1 and 2
kHz.
The degree of hearing loss was categorized in two different
ways: employment of commonly used age-independent
clinical guidelines (International classification of impair-
ments, disabilities and handicaps, World Health Organi-
zation, May 1980, Geneva, Switzerland) and comparison
of thresholds to age-dependant percentiles [9,10]. For
each ear, impairment was evaluated using pure-tone aver-BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/10
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ages (PTAs) for 0.5, 1, and 2 kHz. Impairment was audio-
metrically classified using the following pure-tone
threshold ranges: normal 0 to 25 dB HL; mild, 26 to 40 dB
HL, moderate, 41 to 55 dB HL; moderately severe, 56 to
70 dB HL; severe, 71 to 90 dB HL; and profound, 91 to
110 dB HL. Configuration of hearing loss was classified
according to the European Working Group on Genetics of
Hearing Impairment. Audiometric configurations were
defined as midfrequency U-shaped, 15-dB or more differ-
ence between the poorest thresholds in the midfrequen-
cies and those at higher frequencies; low-frequency
ascending, 15-dB or more from the poorest thresholds to
the higher frequencies; flat, less than 15-dB between 0.25
and 8 kHz; high frequency, 15-dB or more difference be-
tween the mean thresholds at 0.5 and 1 kHz and the mean
thresholds at 4 and 8 kHz. For each subject, impairment
was classified using PTA on the more affected ear.
The age-dependent analysis of the degree of hearing loss
plotted pure-tone air conduction thresholds at .5, 1, 2,
and 4 kHz, and pure-tone averages (PTAs) for .5, 1, 2 kHz,
against corresponding 95th percentiles [9]. Similarly,
pure-tone air conduction thresholds at 8 kHz were plotted
against corresponding 90th percentile values [10]. Ninety-
fifth percentile values for 0.5, 1, 2 and 4 kHz were ob-
tained from a uniformly auditory screened population,
and 90th percentile values for 8 kHz were obtained from
the 1990 International Organization for Standardization
standards. Ninetieth percentile values were chosen for 8
kHz owing to a lack of established 95th percentile data for
this frequency.
The percentage of study subjects with pure-tone thresh-
olds above the 95th percentile was calculated for all tested
men. Bone-conduction thresholds were used for the anal-
ysis. The presence of sensorineural hearing loss was de-
fined as two or more thresholds in one or both ears above
the 95th percentile value (for 0.5, 1, 2 or 4 kHz), or the
90th percentile value for 8 kHz [9,10].
Tympanometric results were categorized according to
standardized values for static compliance and tympano-
metric peak pressure [11].
Statistical analysis
Possible relations of hearing loss to other clinical symp-
toms were investigated by means of non parametrical tests
(Mann-Whitney U tests) owing to the sample sizes <30,
Table 1: Demographics and clinical characteristics of the study population
Patient Age Acroparesthesia Kidney function (51Cr-EDTA
 Glomerular Filtration
 Rate in mL/min/1.73 m2)
Left ventricular
 hypertrophy
Central Nervous 
System involvement
Hearing status (0–5)
 * right ear / left ear
1 50 + Transplant + + (lacuna on MRI) 2/2
2 26 + Normal (98.7) - - 0/0
3 40 + Transplant - - 0/1
4 59 + Severe renal insufficiency (20.9) + + (TIA) 2/2
5 24 + Normal (87) - - 0/0
6 34 + Transplant + - 0/2
7 37 - Severe renal insufficiency (23.5) - + (stroke) 2/5
8 29 + Normal (111.8) - + (TIA) 0/0
9 48 + Transplant + + (Stroke) 5/2
10 40 - Transplant + - 0/0
11 61 - Peritoneal dialysis + Not evaluated 1/3
12 31 + Hemodialysis + + (stroke) 1/1
13 21 + Normal (127) - Not evaluated 0/0
14 50 + Hemodialysis + + (lacuna on MRI) 2/2
15 39 - Severe renal insufficiency (16.4) + - 0/0
16 23 + Normal (111) - + (TIA) 2/2
17 64 + Moderate kidney insufficiency (41.2) + + (lacuna) 0/1
18 36 + Normal (98.7) - - 0/0
19 57 + Moderate kidney insufficiency (59.7) + + (TIA) 5/1
20 35 - Transplant + - 1/1
21 28 + Mild kidney insufficiency (79.2) - - 0/0
22 25 + Normal (114.2) - - 0/0
Hearing impairment: 0: Normal hearing status (0–25 dB HL), 1: mild impairment (26–40 dB HL); 2: moderate impairment (41–55 dB HL), 3: severe 
deafness (56–70 dB HL), 4: profound deafness (91–110 dB HL), 5: >110 dB HL (cophosis)BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/10
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comparing the observed hearing losses in two samples,
namely an impaired and a healthy one relative to the clin-
ical symptom of interest. P < 0.05 was considered signifi-
cant. In the particular case of correlation between mean
PTA and glomerular filtration rate, the scatterplot of data
showed a strongly nonlinear relationship, with data
points tending to cluster along the vertical and horizontal
axes. In this case, patients were split into categories, re-
spectively with normal and impaired hearing of glomeru-
lar filtration rate.
Results
Demographics
Our patients range from 19 to 64 years of age; the mean
age at the time of examination was 39.5 (SD, 13.6) years
old. Table 1 summarizes the major findings for the 22
hemizygous patients of our series.
Auditory symptoms
Ten subjects (45.5%, mean age = 34.8 years, SD = 12.4)
considered their audition as normal. Five patients (mean
age = 41.6 years, SD = 12.5) complained of a progressive
unilateral (n = 1) or bilateral (n = 4) deafness. Seven pa-
tients (mean age = 44.7, SD = 15.9) complained of a sud-
den deafness: 4 patients had a sudden unilateral (n = 2) or
bilateral (n = 2) deafness, and 3 patients had an unilateral
progressive deafness with a sudden deafness on the other
ear. Six patients out of 22 (27.3%) complained of tinni-
tus. Tinnitus occurred in the context of sudden deafness
for 2 patients, and progressive hearing loss for 2 other pa-
tients. In the remaining 2 patients, audition was normal
on the side with tinnitus.
Age-independent analysis of hearing loss
First, an age-independent analysis of the degree of hearing
loss was realized using the age-independent clinical
guideline published by the World Health Organization
(International classification of impairments, disabilities,
and handicaps, presented at: World Health Organization;
May 1980; Geneva, Switzerland). Table 2 gives the mean
air conduction thresholds and PTAs of all ears (n = 44
ears), and their corresponding standard deviations (SD)
versus the age of the affected subjects. All cases of deafness
were sensorineural hearing losses. No conductive or
mixed hearing loss was observed. Mean thresholds were
within normal ranges for young patients (below 30 years
old), and frequencies below 8 kHz, but increased with age
and ranged from mild to severe in higher frequencies.
For each ear, impairment was audiometrically classified
using the PTAs. Approximately 52% (23 of the 44 ears) of
all audiograms had strictly normal PTAs. Audiometric
configurations of the remaining audiograms (n = 21), ac-
cording to the European Work Group on Genetics of
Hearing Impairment, were mid-frequency U-shaped (n =
1), flat (n = 4), high-frequency hearing loss (n = 13), and
cophosis (n = 3).
For each subject, impairment was audiometrically classi-
fied using the PTAs on the more affected ear. Figure 1 il-
lustrates the degree of hearing loss of each subject as a
function of age (n = 22 subjects). Normal hearing was
most common in the 21- to 30-year, and in the 31- to 40-
year age groups, whereas sensorineural hearing loss be-
came more common in the older age groups. Most of pa-
tients after 41 years of age had a mild to profound hearing
loss. Only 50% (11 of 22) of all affected subjects had
strictly normal PTAs for both ears.
Table 2: Mean pure-tone averages (PTAs) and average air conduction thresholds from 125 Hz to 8 kHz as a function of age for affected 
individuals.
Age group (years) 21–30 31–40 41–50 51–60 61–70
Mean  SD (years) 25.1  2.6 36.6  3 50  0 58.3  0.5 62.5  1.7
Number of ears (n = 14) (n = 16) (n = 4) (n = 6) (n = 4)
PTAs, (dBHL)
right ear 15.9 (11.9) 19.6 (13.8) 45.8 (10.6) 100.6 (33.7) 23.3 (14.1)
left ear 19 (19) 34 (37) 51.7 (2.3) 45.5 (9.2) 41.7 (30.6)
Air conduction thresholds
125 Hz 17.1 (16.1) 27.8 (29.8) 33.7 (4.7) 60 (47) 30 (20.4)
250 Hz 15.3 (15.1) 25.3 (28.4) 36.2 (8.5) 64.2 (43.6) 26.3 (22.5)
500 Hz 17.5 (17.5) 25.9 (28.1) 47.5 (5) 73.3 (36.8) 30 (23.8)
1 kHz 16.1 (13.7) 25.6 (28.5) 46.2 (7.5) 74.2 (36.1) 33.7 (21.7)
2 kHz 18.9 (21.7) 28.8 (30.1) 52.5 (11.9) 71.7 (39.3) 33.7 (22.8)
4 kHz 24.6 (19.8) 49.1 (30.1) 62.5 (6.4) 78.3 (32.6) 50 (10.8)
8 kHz 32.1 (31.8) 60.6 (27.6) 67.5 (8.7) 89.2 (25.4) 66.3 (20.2)
Data are given as mean (SD). DBHL = decibels hearing level.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/10
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Comparison of thresholds to age-dependent percentiles
To identify the contribution of Fabry disease to the ob-
served sensorineural hearing loss, audiometric thresholds
at 0.5, 1, 2, 4 and 8 kHz, as well as PTAs, were compared
to those reported for an audiologically screened popula-
tion 25 years and older [9,10]. As shown in Figure 2, 18 of
the 22 patients (82%) had at least two thresholds above
the 95th percentile (for 0.5, 1, 2, and 4 kHz frequencies)
or, in the case of 8 kHz, above the 90th percentile. Figure
3 shows the percentage of study subjects with pure-tone
thresholds above the 95th percentile (for 0.5, 1, 2, 4 fre-
quencies and PTAs) and above the 90th percentile for 8
kHz frequency. The percentage of subjects with pure-tone
thresholds above these limits varied from 56.8% (.5 kHz)
to 86.4% (8 kHz).
Sudden sensory hearing loss
Sudden deafness may be defined as a sensorineural hear-
ing loss that develops over a period of hours or a few days.
Altogether, 7 patients (31.8% of the patients, 20.5% of the
tested ears) had episodes of sudden deafness.
Twenty-six-year-old patient AT (n2) had bilateral sudden
deafness two years ago, which partially reversed with a bi-
therapy (corticosteroids and vasodilatation). Auditory
thresholds are now normal for all frequencies below 4
kHz, but both high frequency hearing loss (70 dB HL at 8
kHz) and bilateral tinnitus aurium remain. Thirty-seven-
year-old patient LO (n7) had a left sudden deafness at
age 12, leading to complete deafness without tinnitus.
Forty-eight-year-old patient PG (n9) had a right sudden
deafness at age 46, responsible for complete deafness
without  tinnitus aurium. Sixty-one-year-old patient FJ
(n11) had a left sudden deafness at age 59, leading to a
severe deafness (PTA= 60 dB HL, flat audiogram). Fifty-
year-old patient HD (n14) had a left sudden deafness
three months ago, leading to moderate deafness (PTA = 50
dBHL, high-frequency configuration). Patient JS (n16)
had a right sudden deafness at only 23 years of age, with
a subsequent residual hearing loss (PTA = 63 dB HL, U-
shaped configuration). Fifty-seven-year-old patient PM
(n19) had a right sudden deafness at age 43, leading to
complete deafness with tinnitus.
Other findings
All patients had type A tympanograms, indicative of nor-
mal middle ear mobility and pressure. Otoacoustic emis-
sions (i.e., distortion product and transient-evoked
otoacoustic emissions) were tested in all subjects, and re-
vealed responses that were consistent with the degree of
hearing loss [12,13]. As expected, emissions were absent
in subjects with auditory thresholds above 30 dB HL in
the range of 1 to 4 kHz. ABR audiometry was realized in
all subjects, and revealed responses that were consistent
with the degree of hearing loss. All intervals between
waves I and V, and III and V were normal which precludes
any significant retrocochlear involvement.
Correlations
i) Kidney function
Cochlear and kidney functions were compared for all 22
hemizygotes affected with classic FD. Kidney function was
assessed by 51-Chrome-EDTA Glomerular Filtration Rate
(GFR). Kidney insufficiency was classified into 4 groups:
end-stage renal disease (GFR below 15 ml/min/1.73 m2),
severe kidney insufficiency (GFR between 16 and 30 ml/
min/1.73 m2), moderate kidney insufficiency (GFR be-
tween 31 and 60 ml/min/1.73 m2), normal kidney func-
tion (GFR above 61 ml/min/1.73 m2).
Out of 22 patients, 9 patients had end-stage renal disease
among which 3 were on dialysis and 6 had received kid-
ney transplantation. Three patients had severe kidney in-
sufficiency. Two patients had moderate kidney
insufficiency. One patient had mild kidney insufficiency.
Seven patients had normal kidney function. In summary,
67% of the patients in this series had an altered kidney
function and 33% had a normal kidney function.
The mean bilateral PTAs (0.5, 1, and 2 kHz) were com-
pared to glomerular filtration rate. In all but two patients
(n = 10) with deafness (mean bilateral PTA>25 dB HL),
glomerular filtration rate was below 40 ml/min/1.73 m2
(Figure 4). In all but one patients (n = 8) with normal kid-
ney function or mild kidney insufficiency (GFR above 60
ml/min/1.73 m2), PTAs were normal or below 20 dB HL.
Figure 1
Degree of hearing loss as a function of age in 22 patients
affected with Fabry disease. Impairment was classified using
pure-tone thresholds (0.5, 1, and 2 kHz; PTAs) on the more
affected ear without any consideration with the age or higher
frequencies (4 and 8 kHz).
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Out of 9 patients on dialysis or with kidney transplanta-
tion, only 2 had normal hearing (PTAs below 25 dB HL).
ii) Cochlear and cerebrovascular manifestations of FD
Patients were also classified according to their cerebrovas-
cular manifestations. For correlation with hearing loss,
the cerebrovascular involvement was classified into either
absence or presence of any neurological clinical symp-
toms (strokes, transient ischaemic attacks) or magnetic
resonance imaging (MRI) lesions (leukoareiosis or lacu-
na). Two patients who did not benefit from MRI were not
included in the statistical analysis. Among the 20 studied
hemizygotes with classic FD, 10 patients (50%) had cere-
brovascular disease, and 10 patients (50%) had no symp-
toms or signs of cerebrovascular disease. A mean bilateral
PTA of 14.9 dB HL (n = 10, SD = 7.9) was observed in pa-
tients with no cerebrovascular symptoms as compared to
a mean PTA of 50.7 dB HL (n = 10, SD = 26.5) in patients
who had cerebrovascular involvement according to the
above classification. Associations between cochlear and
cerebrovascular involvement were analyzed using Mann-
Whitney non parametric test. Cochlear involvement was
significantly higher in FD patients with cerebrovascular
involvement than in FD patients without (P < 0.01).
iii) Cochlear manifestations of FD and left ventricular hypertrophy
Left ventricular hypertrophy (LVH) was defined as septal
wall thickness  13 mm or posterior wall thickness  13
mm. Twelve patients (54.5%) had left ventricular hyper-
trophy. A mean bilateral PTA of 23.4 dB HL (n = 10, SD =
24.9) was observed in patients without LVH, whereas
mean bilateral PTA was 40.3 dB HL (n = 12, SD = 24.8) in
patients with LVH. Using Mann-Whitney non-parametric
test, no statistical difference was seen between the 2
groups (P = 0.3).
Figure 2
Comparison of thresholds for 20 Fabry hemizygotes, aged 25 years and older (circles), with 95th percentile data (squares) from
the International Organization for Standardization 1990 standards for 0.5, 1, 2, 4 frequencies and PTAs or, for 8 kHz, with the
90th percentile. dB HL indicates decibel hearing level.
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Discussion
This study presents the first evidence of the high incidence
of progressive hearing loss, sudden deafness, and tinnitus
aurium in a cohort of 22 male patients affected with Fabry
disease (FD), an orphan lysosomal storage disease. Fifty-
two percent of the patients complained of a progressive (n
= 5) or sudden (n = 7) deafness, and 6 patients had tinnitus
aurium. Approximately 82% of all patients had at least two
auditory thresholds above the 95th percentile for frequen-
cies varying between 0.5 and 4 kHz, or above the 90th per-
centile for the 8 kHz frequency. All cases of deafness were
sensorineural hearing losses.
The origin and the mechanisms of deafness probably in-
volve the inner ear. In our study, no patient had conduc-
tive hearing loss, and all patients had type A
tympanograms, in favor of normal middle ear mobility
and pressure. Distortion products and transient-evoked
otoacoustic emissions responses were consistent with the
degree of hearing loss (i.e., absence of emissions in sub-
jects with auditory thresholds above 30 dB hearing loss
(HL) in the range of 1 to 4 kHz). In this study, ABR audi-
ometry did not reveal any abnormality in intervals be-
tween waves I and V, and waves III and V. In the literature,
clinical histories, audiometric results, and temporal his-
topathology were described [4] for two patients (48- and
59-year-old men) with FD [6]. Both patients demonstrat-
ed a bilateral sloping sensorineural hearing loss. Neu-
ropathologic findings of the inner ear were major and
identical. Evidence of glycosphingolipid accumulation in
the ear in vascular endothelial cells, and in various gangli-
on cells, atrophy of the stria vascularis and the spiral liga-
ment in all cochlear turns was observed in both cases. The
authors concluded that hearing loss was caused by accu-
mulation of glycosphingolipids within the stria vascularis
and ganglion cells.
There could also be an endothelial or vascular component
to deafness in FD patients, due to capillary wall hypertro-
phy, encroaching the lumen. Indeed, globotriaosylcera-
mide (Gb3) accumulates in all cells of the body but has
some key target sites of pathology, and deposition of gly-
cosphingolipids occurs widely in the lysosomes of vascu-
lar endothelial and smooth-muscle cells [5]. Therefore,
hearing loss and more specifically sudden deafness could
also be potentially caused by vascular mechanisms due to
the accumulation of glycosphingolipids within lysosomes
of endothelial and smooth muscle cells leading to pro-
gressive narrowing, ischaemia, and frank occlusion in the
vessels feeding the cochlea.
Finally, although intracellular Gb3 storage represents the
initial insult to the cells, it is possible that a cascade of
pathological mechanisms are involved in the develop-
ment of disease-related complications, as suggested by re-
cent studies which revealed an imbalance in vascular
reactivity and the propensity for a pro-thrombotic state
among patients with FD [14].
Interestingly, we found a correlation between kidney and
cochlear involvement in our population. Most patients
with hearing loss had a decreased glomerular filtration
rate. Among our patients, 9 had severe renal insufficiency
necessitating dialysis or kidney transplantation, and the
Figure 3
Percentage of study subjects with pure-tone thresholds
above the 95th percentile for the 0.5, 1, 2, 4 frequencies and
PTAs, and above the 90th percentile for the 8 kHz frequency
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Glomerular filtration rate (GFR) against mean bilateral pure-
tone averages (0.5, 1, and 2 kHz) in 22 hemizygotes affected
with classic Fabry disease.
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responsibility of hemodialysis and renal transplant in the
occurrence of hearing loss can be questioned. However,
recent studies seem to indicate that neither dialysis nor re-
nal transplant are the main cause of observed deafness in
end-stage renal disease patients [15]. In our patients, the
hearing loss was present in most cases before dialysis or
transplant. However, it is still possible that both dialysis
and transplantation could contribute to worsen a pre-ex-
isting hearing impairment. Cochlear lesions have been de-
scribed in association with kidney insufficiency in various
pathological situations, and pathophysiologic similarities
have been observed between the kidney and the cochlea.
One illustrating example is the common nephrotoxic and
ototoxic component of various drugs or medicines
(aminoglycosides, cisplatinum, furosemide...). For
aminoglycosides the mechanism, although complex,
seems to be related to lysosomal dysfunction. Aminogly-
cosides enter proximal epithelial cells of the kidney
through endocytic vesicles which subsequently fuse with
lysosomes. Aminoglycosides that resist to degradation can
induce an alteration of the lysosomal phospholipase, a
modified permeability of lysosomal membranes and a re-
duction in catabolism of renal proteins inducing phos-
pholipidosis. A decrease of mitochondrial oxidative
phosphorylation, an inhibition of the lysosomal mem-
brane Na/K+ ATPase and the generation of superoxide an-
ion and hydrogen peroxide were also observed. Similar
mechanisms have been observed in the inner ear, specifi-
cally for outer hair cells [16] leading to sensorineural deaf-
ness, mainly on high tone frequencies. In FD, the
lysosomal storage could trigger a similar mechanism with
the epithelial cells of the kidney and the outer hair cells
representing a key target site of pathology. Furosemide
has also both ototoxic and nephrotoxic effects, inhibiting
Na/K/Cl channels which are present on the renal tubular
cells as well as the cells of the stria vascularis. Both exam-
ples appear interesting with respect to the clinical mani-
festations of FD, also affecting both the kidney and
cochlea. Could similarities between the stria vascularis of
the ear and the tubular cells of the kidney explain cochlear
and kidney manifestations in FD through a common
pathophysiology? Could ENT investigations allow to pre-
dict an evolution to end-stage renal disease in patients
demonstrating hearing loss? These hypothesis necessitate
further studies, among which examinations of his-
topathological specimens of the cochlea in patients affect-
ed with FD. Such histopathological pieces are however
extremely rare, due to the rapid deterioration of cochlea
after death, and only 2 patients have been described in the
literature [6]. Histopathological studies of the cochlea ob-
tained from the knock-out mouse models of FD could
also potentially provide interesting data [17,18].
FD is a multisystem disorder associated with a wide varia-
bility in clinical expression and one of the most devastat-
ing features of FD are strokes or cerebrovascular accidents
(CVA). In one study, the mean age at onset of cerebrovas-
cular complications was 33.8 years and the commonest
anatomical localisation for CVA was the vertebrobasilar
territory with a high recurrence rate and reduced life ex-
pectancy [19]. Another study of 33 males reported the in-
cidence of cerebrovascular complications as 24%, with
lesions localised to both the carotid and vertebrobasilar
territories and occurring mostly before the age of 40 [20].
We observed a positive correlation between hearing loss
and cerebrovascular accidents in our cohort of FD pa-
tients, further emphasising the importance of the vascular
component as a likely mechanism for the occurrence of
deafness in FD.
Data are available from several cohort studies, document-
ing a high frequency of left ventricular hypertrophy
(LVH), concentric apical hypertrophy, and intraventricu-
lar septum thickening in FD [21–23]. Age-related progres-
sion of echocardiographic LVH changes, correlating with
disease severity was reported in a cohort of young males,
aged 14–43 years (n = 23) [24]. Out of the 22 patients
evaluated in the present study, 12 (55%) had LVH. Al-
though we found a trend between cochlear involvement
and LVH, statistical significance was not reached. Previous
histopathological studies have shown that glycosphingol-
ipid storage occurs in both cardiac capillaries and cardio-
myocytes in classic FD. However, LVH is observed not
only in the classic form but also in the cardiac variant of
FD in which, interestingly, there is no storage in the vas-
cular endothelium [5]. Therefore, the absence of statisti-
cally significant correlation between hearing loss and LVH
could be in favour of different pathological mechanisms
for these two lesions. Endothelial storage and dysfunction
could be an important feature of the cochlear lesions,
while LVH could be more related to storage in cardiomy-
ocytes and subsequent dysfunction of metabolic path-
ways rather than to vascular involvement. However, our
statistical analysis was limited to LVH (defined as septal
wall thickness  13 mm or posterior wall thickness  13
mm, or cardiac mass > 130 g/m2) assessed by echocardi-
ography or cardiac MRI. It could be interesting to search
whether a positive correlation between heart symptoms
and hearing loss would appear when all cardiac manifes-
tations including ECG modifications such as short PR in-
terval, conduction abnormalities and rhythm
disturbances are considered in the analysis.
Advances in the application of molecular genetic tech-
niques have enabled development of directed protein
therapies in Fabry disease. To a large extent, this milestone
has resulted in a shift in the management paradigm of-
fered to patients from an approach that relied on predic-
tive genetic counseling and palliative care to the genuine
possibility of offering early diagnosis and active interven-BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/10
Page 9 of 10
(page number not for citation purposes)
tion. However, the heterogeneity of clinical expression,
the paucity of reliable markers and the uncertainty a priori
of being able to reverse the disease create a problem in the
selection of the appropriate endpoints to evaluate the ef-
ficacy of therapeutic interventions [7,8]. Similarly, the de-
cision to initiate enzyme replacement therapy (ERT) in
asymptomatic patients is confounded by the variability of
the phenotype and the absence of surrogate markers that
reliably predict the pattern of organ involvement and dis-
ease severity. With this respect, our extensive evaluation of
cochlear functions in a cohort of male patients affected
with FD, demonstrating the high incidence of both pro-
gressive and sudden deafness, should prove useful in de-
lineating the importance of cochlear lesions in the natural
history of FD. We recommend an audiogram to be system-
atically performed in each FD patient prior to initiate ERT.
Indeed, it could possibly serve as an additional endpoint
for establishing whether enzyme replacement is effective
in reducing or eliminating the incidence of FD-related
hearing impairment. However, in view of the various pos-
sible mechanisms of hearing loss in FD, palliative meas-
ures may continue to be important in conjunction with
ERT to achieve complete patient response or disease con-
trol, specifically if outer haired cells are destroyed.
Finally, we have also demonstrated that high tone deaf-
ness, usually not clinically significant but definitely con-
firmed by audiograms, was present at young age in
hemizygotes. This is an important consideration because
it is likely that delayed treatment, at a stage when ad-
vanced tissue changes (e.g., cochlear sclerosis or outer
cells death) are established may not lead to full recovery
and represent persistent sources of morbidity. This data
further emphasize that early therapeutic intervention
should offer increased possibilities of mitigating the dis-
ease process in Fabry disease [25].
Conclusion
This is the first evidence of a high incidence of both pro-
gressive hearing impairment and sudden deafness in a co-
hort of male patients affected with Fabry disease. Hearing
loss on high-tone frequencies was also found on audio-
grams in Fabry patients with clinically "normal" audition,
despite their young age at time of examination. The inci-
dence of hearing loss appeared significantly increased in
Fabry patients with kidney failure or cerebrovascular le-
sions.
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